TCF7L2 and breast carcinoma: Additionally, the TCF7L2 rs12255372 displayed significant association with decreased risk of breast cancer in ER- (OR, 0.105, CI, 0.013–0.853, p = 0.01351) category similar to that in the overall population but not in the ER + cohort.